Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,773,752
  • Shares Outstanding, K 192,114
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 596 M
  • EBITDA $ 685 M
  • 60-Month Beta 0.27
  • Price/Sales 3.57
  • Price/Cash Flow 17.01
  • Price/Book 1.75

Options Overview Details

View History
  • Implied Volatility 32.56% (+0.04%)
  • Historical Volatility 54.07%
  • IV Percentile 31%
  • IV Rank 20.41%
  • IV High 55.63% on 04/10/25
  • IV Low 26.64% on 03/24/25
  • Expected Move (DTE 1) 0.75 (1.35%)
  • Put/Call Vol Ratio 1.34
  • Today's Volume 1,748
  • Volume Avg (30-Day) 1,778
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 41,871
  • Open Int (30-Day) 41,721
  • Expected Range 54.49 to 55.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.67
  • Number of Estimates 10
  • High Estimate 0.85
  • Low Estimate 0.10
  • Prior Year 0.72
  • Growth Rate Est. (year over year) -6.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.47 +7.33%
on 12/16/25
63.89 -13.53%
on 12/19/25
+3.13 (+6.00%)
since 12/15/25
3-Month
50.76 +8.84%
on 11/07/25
63.89 -13.53%
on 12/19/25
+2.15 (+4.06%)
since 10/15/25
52-Week
50.76 +8.84%
on 11/07/25
73.51 -24.85%
on 03/07/25
-6.34 (-10.29%)
since 01/15/25

Most Recent Stories

More News
BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry

BMRN : 55.12 (-1.71%)
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

APPN : 29.85 (-1.97%)
PVH : 67.53 (+2.94%)
BMRN : 55.12 (-1.71%)
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

SAN RAFAEL, Calif. , Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present...

BMRN : 55.12 (-1.71%)
Veeva and BioMarin Form Long-Term Strategic Partnership

Partnership to help BioMarin increase speed and efficiency  in developing and commercializing innovative therapies

VEEV : 219.04 (+0.08%)
BMRN : 55.12 (-1.71%)
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics...

FOLD : 14.32 (-0.42%)
BMRN : 55.12 (-1.71%)
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BMRN : 55.12 (-1.71%)
A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

FOLD : 14.32 (-0.42%)
BMRN : 55.12 (-1.71%)
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

BMRN : 55.12 (-1.71%)
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Gain Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth...

FOLD : 14.32 (-0.42%)
BMRN : 55.12 (-1.71%)
1 Oversold Stock Primed to Rebound and 2 That Underwhelm

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

SHW : 355.15 (+0.23%)
BMRN : 55.12 (-1.71%)
CHD : 90.30 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 57.73
2nd Resistance Point 57.05
1st Resistance Point 56.56
Last Price 55.12
1st Support Level 55.40
2nd Support Level 54.72
3rd Support Level 54.23

See More

52-Week High 73.51
Fibonacci 61.8% 64.82
Fibonacci 50% 62.14
Fibonacci 38.2% 59.45
Last Price 55.12
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar